Literature DB >> 30945022

Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation.

Mariana Robatto1,2, Maria Clara Pavie1,2, Igor Garcia1, Manoela Porto Menezes1,2, Milena Bastos1, Handerson Jorge Dourado Leite1, Andreia Noites3, Patrícia Lordelo4,5.   

Abstract

Vulvovaginal candidiasis (VVC) is a frequent infection of the female genitourinary tract. It is considered the second most common genital infection in women, after bacterial vaginosis. VVC is treated with oral or topical azole derivatives. However, these agents may lead to adverse reactions and their chronic use might lead to resistance to antifungal agents. Given that the ultraviolet A/blue light-emitting diode (LED) is an electromagnetic radiation source with antimicrobial properties, it is hypothesized that this resource may be a non-drug alternative to the treatment of vulvovaginitis. A technical/experimental safety test was conducted to characterize the light source spectrum and temperature generation of the device, followed by a pilot study in a 52-year-old patient with a clinical diagnosis of VVC confirmed by culture and examination of fresh vaginal samples, owing to the presence of lumpy vaginal discharge and a complaint of pruritus. The vulva and vagina were exposed to 401 ± 5 nm ultraviolet A/blue LED irradiation in a single session, divided into two applications. A reassessment was performed 21 days after the treatment. The light-emitting device had a visible spectrum, in the violet and blue ranges, and a maximum temperature increase of 7 °C. During the reassessment, the culture was found to be negative for fungus, and the signs and symptoms of the patient had disappeared. A light-emitting device with a spectrum in the range of 401 ± 5 nm could potentially be an alternative treatment modality for women with VVC, as it led to the resolution of clinical and microbiological problems in our patient.

Entities:  

Keywords:  Phototherapy; Vulvovaginal candidiasis; Women

Mesh:

Year:  2019        PMID: 30945022     DOI: 10.1007/s10103-019-02782-9

Source DB:  PubMed          Journal:  Lasers Med Sci        ISSN: 0268-8921            Impact factor:   3.161


  20 in total

Review 1.  Probiotics for vulvovaginal candidiasis in non-pregnant women.

Authors:  Huan Yu Xie; Dan Feng; Dong Mei Wei; Ling Mei; Hui Chen; Xun Wang; Fang Fang
Journal:  Cochrane Database Syst Rev       Date:  2017-11-23

2.  Helicobacter pylori in patients can be killed by visible light.

Authors:  Robert A Ganz; Jennifer Viveiros; Aamir Ahmad; Atosa Ahmadi; Ayesha Khalil; M Joshua Tolkoff; Norman S Nishioka; Michael R Hamblin
Journal:  Lasers Surg Med       Date:  2005-04       Impact factor: 4.025

3.  Light therapy by blue LED improves wound healing in an excision model in rats.

Authors:  Natalia Adamskaya; Peter Dungel; Rainer Mittermayr; Joachim Hartinger; Georg Feichtinger; Klemens Wassermann; Heinz Redl; Martijn van Griensven
Journal:  Injury       Date:  2011-09       Impact factor: 2.586

Review 4.  Treatment of vulvovaginal candidiasis: a review of the literature.

Authors:  Andraž Dovnik; Andrej Golle; Dušan Novak; Darja Arko; Iztok Takač
Journal:  Acta Dermatovenerol Alp Pannonica Adriat       Date:  2015

5.  Interaction of photodynamic therapy and hyperthermia: tumor response and cell survival studies after treatment of mice in vivo.

Authors:  B W Henderson; S M Waldow; W R Potter; T J Dougherty
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

6.  An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis.

Authors:  Paul L Fidel; Melissa Barousse; Terri Espinosa; Mercedes Ficarra; Joy Sturtevant; David H Martin; Alison J Quayle; Kathleen Dunlap
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

Review 7.  Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches.

Authors:  Shu Yih Chew; Leslie Thian Lung Than
Journal:  Mycoses       Date:  2016-01-13       Impact factor: 4.377

Review 8.  Facts and myths on recurrent vulvovaginal candidosis--a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy.

Authors:  Per-Anders Mårdh; Acacio G Rodrigues; Mehmet Genç; Natalia Novikova; J Martinez-de-Oliveira; Secondo Guaschino
Journal:  Int J STD AIDS       Date:  2002-08       Impact factor: 1.359

9.  Epidemiologic features of Vulvovaginal Candidiasis among reproductive-age women in India.

Authors:  Sujit D Rathod; Jeffrey D Klausner; Karl Krupp; Arthur L Reingold; Purnima Madhivanan
Journal:  Infect Dis Obstet Gynecol       Date:  2012-10-15

10.  Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis.

Authors:  Mu-Biao Liu; Su-Rong Xu; Yan He; Guan-Hua Deng; Hua-Fang Sheng; Xue-Mei Huang; Cai-Yan Ouyang; Hong-Wei Zhou
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

View more
  1 in total

1.  Blue light inactivation of the enveloped RNA virus Phi6.

Authors:  Petra Vatter; Katharina Hoenes; Martin Hessling
Journal:  BMC Res Notes       Date:  2021-05-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.